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Abstract
Human respiratory syncytial virus (hRSV) and human metapneu-
movirus (hMPV), two members of the Pneumoviridae family,
account for the majority of severe lower respiratory tract infec-
tions worldwide in very young children. They are also a frequent
cause of morbidity and mortality in the elderly and immunocom-
promised adults. High levels of neutralizing antibodies, mostly
directed against the viral fusion (F) glycoprotein, correlate with
protection against either hRSV or hMPV. However, no cross-neutra-
lization is observed in polyclonal antibody responses raised after
virus infection or immunization with purified F proteins. Based on
crystal structures of hRSV F and hMPV F, we designed chimeric F
proteins in which certain residues of well-characterized antigenic
sites were swapped between the two antigens. The antigenic
changes were monitored by ELISA with virus-specific monoclonal
antibodies. Inoculation of mice with these chimeras induced poly-
clonal cross-neutralizing antibody responses, and mice were
protected against challenge with the virus used for grafting of the
heterologous antigenic site. These results provide a proof of princi-
ple for chimeric fusion proteins as single immunogens that can
induce cross-neutralizing antibody and protective responses
against more than one human pneumovirus.
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Introduction
Human respiratory syncytial virus (hRSV) is the leading cause
worldwide of severe acute lower respiratory tract infections (ALRI,
mainly bronchiolitis and pneumonia) in infants and very young chil-
dren. The estimated new cases of ALRI each year owing to hRSV
infections are more than 33 million in children younger than
5 years, with 10% of these resulting in hospital admissions. hRSV
infections also cause 60,000–120,000 deaths each year in young chil-
dren, with 90% occurring in developing countries (Nair et al, 2010;
Shi et al, 2017). Human metapneumovirus (hMPV) is also a virus of
clinical significance (van den Hoogen et al, 2001), second only to
hRSV as a cause of ALRI in young children (Edwards et al, 2013;
Schuster & Williams, 2013). Both hRSV and hMPV also have a clini-
cal impact in the elderly and in adults with cardiopulmonary disease
or impaired immune systems (Hall et al, 1986; Dowell et al, 1996;
Falsey et al, 2005; Panda et al, 2014). hRSV and hMPV have been
recently reclassified in the orthopneumovirus and metapneumovirus
genera, respectively, of the newly created Pneumoviridae family,
which was detached from the original Paramyxoviridae family
(Afonso et al, 2016). Hence, hRSV and hMPV share clinical and
biological features, although they also have important differences,
for example, in the number of genes or in the proteolytic processing
of their respective fusion (F) glycoproteins (van den Hoogen et al,
2002).
Both hRSV and hMPV genomes encode three glycoproteins (SH,
G, and F) that are inserted in the viral membrane. SH is a small
hydrophobic protein whose function is still unclear and is incorpo-
rated in low amounts into the virus particle (Bao et al, 2008; Gan
et al, 2012). G is a heavily glycosylated and highly variable type II
glycoprotein that resembles mucins and serves as the viral attach-
ment protein (Levine et al, 1987; Thammawat et al, 2008). Finally,
F is a type I glycoprotein that fuses the viral and cell membranes at
the initial stages of an infectious cycle and is the main target of
neutralizing antibodies (for a recent review Melero & Mas, 2015).
The F protein is synthesized as a F0 precursor that requires
proteolytic processing to become functional. While hMPV F is
cleaved only once by trypsinlike proteases outside the cell (Shi-
rogane et al, 2008), hRSV F is cleaved twice inside the cell at two
polybasic sites recognized by furinlike proteases (Gonzalez-Reyes
et al, 2001; Zimmer et al, 2001; Begona Ruiz-Arguello et al, 2002).
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Both hRSV F and hMPV F are trimers of disulfide-linked heterodi-
mers, and these F proteins initially fold into a metastable prefusion
conformation. During membrane fusion, the F glycoprotein refolds
through a series of unstable intermediates into a highly stable post-
fusion conformation that shares some neutralizing epitopes with the
prefusion conformation (Lamb et al, 2006; McLellan et al, 2013b).
There are no available vaccines for either hRSV or hMPV despite
being greatly needed. A wealth of data support the conclusion that
neutralizing antibodies are the major players in protection against
hRSV and hMPV infections (for a recent review Melero & Mas,
2015). The majority of these antibodies are directed against the F
glycoprotein (Walsh & Hruska, 1983), and it was recently shown
that most of the hRSV-neutralizing activity present in human sera
was due to antibodies specific for the metastable prefusion F confor-
mation (Magro et al, 2012; Ngwuta et al, 2015).
The search for new hRSV vaccines has been reinvigorated by
recent advances in structure-based design of soluble hRSV F
proteins folded in either the prefusion (McLellan et al, 2013a;
Krarup et al, 2015) or postfusion conformations (McLellan et al,
2011b; Swanson et al, 2011). Stabilized soluble forms of prefusion
hRSV F were shown to induce higher levels of neutralizing antibod-
ies than soluble postfusion hRSV F in mice, cotton rats, and non-
human primates (McLellan et al, 2013a; Krarup et al, 2015; Palomo
et al, 2016). However, postfusion F, which has the advantage of
being highly stable, can induce sizeable levels of neutralizing anti-
bodies and afford protection against hRSV because it shares certain
epitopes with prefusion F (Swanson et al, 2011). Recently, the struc-
ture of a soluble form of postfusion hMPV F was determined, reveal-
ing extensive similarity with postfusion hRSV F despite having only
~38% sequence identity (Mas et al, 2016). In addition, the purified
postfusion hMPV F protein was able to elicit high titers of neutraliz-
ing antibodies in mice (Mas et al, 2016).
A few monoclonal antibodies capable of neutralizing both hRSV
and hMPV have been reported (Corti et al, 2013; Schuster et al,
2014; Mas et al, 2016); however, no significant cross-neutralization
was detected in polyclonal antibody responses elicited by soluble
postfusion forms of either hRSV F or hMPV F (Mas et al, 2016).
Based on knowledge gained about the antigenic structure of these
two proteins, we engineered a series of chimeric proteins in which
certain epitopes of hRSV F were grafted onto hMPV F and vice
versa. When mice were inoculated with the purified chimeras, they
elicited antibodies that neutralized both hRSV and hMPV. Further-
more, in cases that were tested, immunization of mice with the
chimeric proteins afforded protection against a challenge with the
virus used for grafting of the heterologous antigenic site. Passive
transfer of the mouse sera also reduced significantly lung virus titer
after challenge, demonstrating the prominent role of antibodies in
the protection provided by the chimeric F proteins.
Results
The plasmids encoding each of the chimeric proteins shown in
Fig EV1 were generated and tested for transient expression of the
matching F proteins in CV-1 cells, as described in Materials and
Methods. Some chimeric proteins were expressed at very low or
undetectable levels and were not further analyzed. Chimeric
proteins that reached expression levels above 10% of the wild-type
protein were incorporated into vaccinia virus recombinants for
expression and further antigenic and immunogenic characterization
as described in subsequent sections.
Expression and characterization of postfusion hMPV F with
antigenic site II from hRSV F
Based on the similarity of hMPV F and hRSV F antigenic site II struc-
tures (Mas et al, 2016), it was expected that certain amino acids
could be exchanged between the two proteins without disrupting
the overall local folding (Mas et al, 2016). Indeed, the chimeric
proteins F-414, F-415, and F-416 (Fig EV1), with increasing
numbers of hRSV F residues replacing the equivalent postfusion
hMPV F residues, were expressed at high level and therefore initi-
ally analyzed. Since the expression level of F-414 turned out to
be the same as that of F-415, the former protein was not further
considered.
Much of the C-terminal helix of hMPV F site II in F-415 was made
hRSV-like by swapping seven amino acids unique to each protein
(Fig 1A and B). Additionally, the chimeric F-416 protein incorpo-
rated six further amino acid changes in the hMPV F backbone to
reproduce almost entirely the amino acid sequence of hRSV F site II
(Fig 1A and B). Both F-415 and F-416 were readily purified to homo-
geneity by Ni2+ chromatography followed by gel filtration and
showed the characteristic cone shape of postfusion hMPV F (Mas
et al, 2016) when examined by negative stain EM (Fig EV2).
When tested for binding to site-specific mAbs, F-415 had lost
reactivity with the hMPV F site II mAbs MF9, MF12, MF14, and
MF15 but retained reactivity with the hMPV F site IV-specific mAb
MF16; in addition, it gained full and partial reactivity with the hRSV
F site II mAbs motavizumab (Mz) and 47F, respectively (Fig 1C).
F-416 also lost reactivity with hMPV F site II-specific mAbs but
gained full reactivity not only with Mz but also with 47F (Fig 1C).
To have a better estimate of the affinities of Mz and 47F for the
chimeric proteins, the binding of their respective Fab fragments to
wild-type postfusion hRSV F and the chimeric F proteins was
assessed by surface plasmon resonance (SPR) (Fig 2). Mz Fab
bound to the F-415 and F-416 chimeras with a kon similar to that
observed for the wild-type postfusion hRSV F but showed a much
faster koff for F-415 than for the wild-type and F-416 proteins.
Consequently, Mz affinity for the F-416 chimera was similar to that
for postfusion hRSV F but was markedly decreased for F-415 (see
KD values).
No binding of 47F Fab to F-415 was detectable (Fig 2), and
although binding of 47F Fab to F-416 was quantifiable—with a
slightly faster kon compared with wild-type postfusion hRSV F—a
much faster koff reduced its affinity for F-416 by 10-fold compared to
postfusion hRSV F. Therefore, although site II of F-415 and particu-
larly F-416 protein resembled the antigenic properties of this site in
hRSV F, there were some remaining distinguishable differences
between wild-type and chimeric proteins.
We noted that although ELISA binding of Mz and 47F to the
chimeric proteins followed the same trend as that of their Fab frag-
ments in SPR, significant differences could be perceived with the
two methods. Thus, whereas binding of 47F Fab to F-415 was negli-
gible by SPR (Fig 2), substantial binding of mAb 47F to F-415 was
observed in the ELISA (Fig 1C). Similarly, although binding of mAb
Mz to F-415 was comparable to postfusion hRSV F in the ELISA, a
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substantial reduction in Mz Fab affinity for this chimeric protein
was observed by SPR. These differences are likely due to the higher
density of proteins bound to the ELISA plates than to the SPR chips
and the bivalent nature of antibodies compared with the monova-
lent Fabs.
To assess the immunogenicity of the F-415 and F-416 chimeras,
groups of five mice were inoculated twice (4 weeks apart) i.m. with
10 lg/dose of each purified protein adjuvanted with CpG. The same
inoculation regimen was used for postfusion hRSV F and hMPV F,
as controls. Three weeks after the last immunization, mice were
bled and their sera tested in ELISA for antibody binding to the wild-
type postfusion forms of either hRSV F or hMPV F (Fig 3A). As
reported, the wild-type postfusion F proteins induced high levels of
antibodies that bound to the homologous protein but failed to bind
(or bound very poorly in the case of serum from mice inoculated




Figure 1. Antigenic characterization of postfusion hMPV F chimeras with amino acids from hRSV F antigenic site II.
A Partial amino acid sequences of the hMPV F (blue) and hRSV F (red) antigenic site II (Toiron et al, 1996; Lopez et al, 1998; McLellan et al, 2011b). Partial sequences of
the F-415 and F-416 chimeras are color coded to indicate the origin of their antigenic site II residues. Amino acids shared by hMPV F and hRSV F are colored purple.
The remaining sequences of F-415 and F-416 are derived from hMPV F.
B Surface representation of the hMPV F structure in the postfusion conformation (Mas et al, 2016). One of the protomers is shown as a blue ribbon. Antigenic site II is
magnified and colored as in (A) for the F-415 and F-416 chimeras.
C ELISA binding results of mAbs specific for hRSV F (left panels) or hMPV F (right panels) with the proteins indicated on the left. mAbs specific for hRSV F bind epitopes
of antigenic site II (Mota and 47F) or antigenic site IV (101F). mAs specific for hMPV F bind epitopes of antigenic site II (MF9, MF12, MF14, and MF15) or antigenic site
IV (MF16).
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(Mas et al, 2016). In contrast, the antibodies induced by the F-415
chimera showed substantial binding not only to hMPV F but also to
the hRSV postfusion F protein (Fig 3A). The level of antibody bind-
ing to postfusion hRSV F was even higher with sera from mice inoc-
ulated with F-416 and significantly higher (P < 0.001) than sera
from mice inoculated with wild-type hMPV F.
To assess whether the antibody binding to hRSV F observed with
sera from mice inoculated with F-415 or F-416 was reflected in
neutralizing activity against this virus, the mouse sera were tested
in a microneutralization assay (Fig 3B). Again, the sera of mice
inoculated with the wild-type hMPV F or hRSV F protein had
substantial neutralization titers (IC50) only against the homologous
virus. In contrast, the sera of mice inoculated with either F-415 or F-
416 had sizeable neutralization titers against hRSV, in addition to
neutralizing hMPV. In summary, the antigenic characteristics of the
F-415 and F-416 chimeras, reflected in their reactivity with hRSV F
Figure 2. Binding of Fabs to wild-type and chimeric proteins measured by surface plasmon resonance.
Binding of Mz and 47F Fabs to the immobilized proteins indicated on the left. Sensorgrams of eight different concentrations are shown in each panel. The calculated binding
parameters are shown in the table. Red lines indicate the best fit of the data to a 1:1 binding model. RUs, response units.
EMBO Molecular Medicine Vol 10 | No 2 | 2018 ª 2017 The Authors
EMBO Molecular Medicine Chimeric Pneumoviridae fusion proteins Eduardo Olmedillas et al
178
site II-specific mAbs (Fig 1C), correlated with their capacity to
induce murine antibodies that bound hRSV F and neutralized hRSV
infectivity, which was particularly prominent in the case of F-416.
We note, however, that in some sera no quantitative correlation
was found between binding and neutralization titers; for example,
serum from mouse #5 inoculated with F-415 had low levels of hRSV
F-binding antibodies (Fig 3A) but neutralized hRSV very efficiently
(Fig 3B).
To evaluate whether induction of hRSV-neutralizing antibodies
by the chimeric proteins could be correlated with protection against
a challenge with this virus, groups of eight mice were immunized
three times, 4 weeks apart, with 20 lg of either F-415 or F-416 adju-
vanted with CpG. One week after the last injection, mice were chal-
lenged intranasally with hRSV (A2 strain), and 5 days later, the
amount of virus in lung extracts was quantified in a plaque assay.
In parallel, three groups of five mice were inoculated with either
CpG or wild-type postfusion hRSV F or hMPV F, as controls.
The results again demonstrated a significant increase in hRSV-
neutralizing antibodies in the sera of mice inoculated with F-415
and F-416, just before the challenge, compared with CpG-only and
postfusion hMPV F controls (Fig 4A). Although there was some
spread of the hRSV-neutralizing titers of individual mice, those inoc-
ulated with F-416 had on average higher neutralization titers than
those inoculated with F-415. However, in both groups some individ-
ual mouse titers reached values close to those of mice inoculated
with postfusion hRSV F.
Reduction in hRSV replication in the lungs of inoculated mice
clearly correlated with the noted induction of antibodies that
neutralized hRSV infectivity (Fig 4B). Whereas hRSV reached high
titers in the lungs of mice inoculated with either CpG or hMPV F,
there was no detectable virus in the lungs of mice inoculated with
postfusion hRSV F. Two of the mice inoculated with the F-415
chimera (#6 and #7) had no detectable virus in their lungs. These
two mice also had the higher titers of hRSV-neutralizing antibodies
in their sera (compare Fig 4A and B). As a group, mice inoculated
with F-415 protein had a substantial reduction in lung virus titers
compared with CpG and hMPV F controls. Remarkably, the lungs of
all mice inoculated with F-416 were free of detectable virus, demon-
strating the efficacy of F-416 vaccination for protection against hRSV
infection.
To further substantiate the relevance of antibodies in protection
of mice inoculated with F-415 or F-416 chimeras, sera from each
group of mice of Fig 4B were pooled together and passively trans-
ferred i.p. to new mice that were challenged the following day with
the same amount of virus as in Fig 4. Five days after challenge, the
amount of virus in lung extracts was quantified in a plaque assay.
The results of Fig EV3 demonstrate that virus replicated to high
titers in mice that received sera from those previously inoculated
with either CpG or hMPV F. In contrast, no virus was detected in
the lungs of mice that received sera from mice previously inoculated
with hRSV F. Most importantly, virus titers were significantly
reduced in mice that received sera from those previously inoculated
A B
Figure 3. Antibody responses of mice inoculated twice with either wild-type proteins or chimeric proteins with a postfusion hMPV F backbone.
Groups of BALB/c female mice (n = 5) were inoculated twice (4 weeks apart) i.m. with 10 lg/dose of the proteins indicated at the top of each panel, folded in their respective
postfusion conformations. One week after the last dose, mice were sacrificed and their blood collected.
A Each mouse serum (identified by a number) was tested in ELISA for antibody binding to the postfusion F proteins indicated at the bottom. The results represented in
the y-axis for each individual mouse serum correspond to the inverse dilution that gave 50% of maximal binding, expressed in log10 units (EC50 (log10)). *P = 0.00045.
B Mouse sera were also tested in microneutralization assays with hRSV and hMPV, as indicated at the bottom. The results represented in the y-axis correspond to the
inverse dilution that inhibited 50% of the viral infectivity (IC50 (log10)). P-values: *P = 0.01001 and **P = 0.00271.
Data information: Each number represents an individual mouse. Short horizontal bars indicate mean values for each group. P-values were calculated as indicated under
“Statistical Analysis”. Only relevant P-values are shown. Differences were considered significant when P < 0.05. Long horizontal lines indicate detection limits.
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with F-415 and particularly with F-416 in which about ten times less
virus was found in their lungs than in those from the CpG- and
hMPV-negative controls (Fig EV3). It is worth noting though that
protection afforded passively by sera from mice previously inocu-
lated with F-416 did not reach the level of protection provided by
sera from mice previously inoculated with hRSV F.
Expression and characterization of prefusion hRSV F with
antigenic site IV from hMPV F
It has been recently demonstrated that most of the neutralizing anti-
bodies in human sera are directed against the prefusion form of
hRSV F (Magro et al, 2012; Ngwuta et al, 2015) and that prefusion-
specific site Ø mAbs are the most potent neutralizing antibodies
(McLellan et al, 2013b; McLellan, 2015). For this reason, and to test
the possibility of extending the chimera approach to other confor-
mations and antigenic sites, the chimeric proteins F-410, F-411, and
F-412 of Fig EV1 were produced. These proteins were derived from
soluble hRSV F stabilized in the prefusion conformation as previ-
ously reported (McLellan et al, 2013a). Although F-412 was
expressed at a moderate level, it failed to react with hMPV F site IV
mAbs, and thus, it was discontinued from the study.
In the F-410 protein, five amino acids of antigenic site IV were
swapped with the corresponding residues of hMPV F (Fig 5A and
B). Six further amino acid changes were introduced in the F-411
chimera to make it more hMPV-like. Both F-410 and F-411 were
purified to homogeneity and had the characteristic globular shape of
prefusion hRSV F, as seen by EM (Fig EV4).
The antigenic properties of F-410 and F-411 proteins were
assessed by ELISA with mAbs specific for the hRSV F and hMPV F
proteins. F-410 showed reduced reactivity with mAb 107F (specific
for hRSV F site IV) and gained some reactivity with mAb MF16
(specific for site IV of hMPV F) (Fig 5C). Similarly, F-411 showed a
complete loss of mAb 107F binding but gained increased reactivity
with mAb MF16 and some reactivity, although much reduced, with
MF20. mAb 101F, which cross-reacts with both hRSV F and hMPV F
site IV (Mas et al, 2016), reacted with all wild-type and chimeric
proteins (Fig 5C).
To demonstrate further that F-410 and F-411 retained the
prefusion characteristics of their hRSV F backbone, their reactiv-
ity with conformation-specific antibodies was determined
(Fig EV5). Both F-410 and F-411 retained reactivity with three
mAbs (D25, AM22, and 5C4) that recognize epitopes in the prefu-
sion-specific site Ø of hRSV F (McLellan et al, 2013b). The two
chimeric proteins also reacted with two mAbs (14402 and 11569)
specific for the recently identified prefusion hRSV F antigenic site
V (Gilman et al, 2016). In contrast, F-410 and F-411 failed to react
with three mAbs (114F, 116F, and 117F) that recognize the six-
helix-bundle motif characteristic of postfusion hRSV F (Rodriguez
et al, 2015).
F-410 and F-411 were then used to immunize groups of five mice
(two doses of 10 lg mixed with CpG) to assess their capacity to
induce hMPV-specific antibodies. The ELISA binding results
revealed essentially no cross-reactivity with the sera of mice inocu-
lated with the prefusion hRSV F or the postfusion hMPV F.
However, a substantial increase in hMPV F binding was noted with
A B
Figure 4. Protection against hRSV challenge with hMPV F backbone chimeras.
Groups of BALB/c mice (n = 5) were inoculated three times, 4 weeks apart, with 20 lg of the postfusion F proteins indicated above each panel. One group (n = 5) was
inoculated only with the CpG adjuvant, as indicated. Two other groups of mice (n = 8) were similarly inoculated with either F-415 or F-416, as indicated at top of the panels.
A Mouse sera, collected just before challenging with hRSV (A2 strain), were used in microneutralization assays against the viruses indicated at bottom. *P = 0.00085
and **P = 0.01986.
B Five days after virus inoculation, mice were sacrificed and the amount of virus in lung extracts was measured in a plaque assay. Mean virus titer for each group is
indicated by short horizontal bar.
Data information: Each number represents an individual mouse. Short horizontal bars indicate mean values for each group. P-values were calculated as indicated under
“Statistical Analysis”. Only relevant P-values are shown. Differences were considered significant when P < 0.05. Long horizontal lines indicate detection limits.
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sera from mice inoculated with F-410 and particularly F-411, in
comparison with sera from mice inoculated with prefusion hRSV F
(Fig 6A).
A substantial increase in hMPV neutralization was also noted in
the sera of mice inoculated with F-410 and especially F-411,
compared with the hRSV F control (Fig 6B). We noted that immu-
nization of mice with either prefusion hRSV F or postfusion hMPV F
did not induce significant cross-neutralization, as reported (Mas
et al, 2016), despite the reports of a few cross-neutralizing mAbs,
like 101F (Mas et al, 2016) or 54G10 (Schuster et al, 2014).
Discussion
The concept of “universal” vaccines (Nabel & Fauci, 2010) has
recently attracted much attention. In some cases, such as influenza
virus (Kanekiyo et al, 2013; Krammer & Palese, 2014; Yassine et al,
2015) or human immunodeficiency virus (HIV) (Kwong et al, 2013),
a universal vaccine is sought to overcome strain variability so that a
single immunogen designed to reorient the antibody response
toward relatively conserved antigenic regions would protect against
infections with highly divergent antigenic variants. In other cases,
A C
B
Figure 5. Antigenic characterization of prefusion hRSV F chimeras with amino acids from hMPV F antigenic site IV.
A Partial amino acid sequences of the hRSV F (red) and hMPV F (blue) antigenic site IV (Lopez et al, 1998; Wu et al, 2007; McLellan et al, 2010). Partial sequences of the
F-410 and F-411 chimeras, color coded to indicate the origin of their antigenic site IV residues. Amino acids shared by hMPV F and hRSV F are shown in purple. The
remaining sequences of F-410 and F-411 are derived from prefusion hRSV F.
B Surface representation of the hRSV F structure stabilized in the prefusion conformation, as reported (McLellan et al, 2013a). One of the protomers is shown as a red
ribbon. Antigenic site IV is magnified and colored as in (A) for the F-410 and F-411 chimeras. Yellow sticks represent a disulfide bridge between Cys416 and Cys422.
C ELISA binding results of mAbs specific for hRSV F (left panels) or hMPV F (right panels) with the proteins indicated on the left. mAbs specific for hRSV F bind to
epitopes of antigenic site Ø (D25), antigenic site II (Mz and 47F), or antigenic site IV (101F and 107F). mAs specific for hMPV F bind to epitopes of antigenic site II
(MF14), antigenic site IV (MF11, MF16, and MF29), or an epitope shared by hRSV F and hMPV F (MPE8). 101F epitope is also shared by hRSV F and hMPV F.
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the aim is to develop vaccines that will cross-protect against
related viruses from the same family, such as the Flaviviridae Zika
and dengue viruses (Barba-Spaeth et al, 2016). Beyond viruses,
universal vaccines are also being designed for Neisseria meningi-
tidis with chimeric variants of the factor H binding protein that
incorporate epitopes of highly divergent bacterial strains (Scarselli
et al, 2011).
In this study, we have produced chimeric proteins of hRSV F and
hMPV F. Together, these two viruses represent the major global
burden of ALRI in very young children. Since palivizumab (Pz), a
humanized neutralizing murine mAb (The IMpact-RSV Study Group
1998) currently used for prophylactic treatment of infants, recog-
nizes an epitope of hRSV F antigenic site II, this site has received
much attention in the hRSV vaccine field. The structure of hRSV F
site II is a helix–turn–helix motif (Toiron et al, 1996) conserved in
the prefusion and postfusion conformations of the F protein. Thus,
hRSV F site II has been grafted onto different protein scaffolds to
focus the antibody responses elicited against those unnatural anti-
gens to a site in hRSV F, which is recognized by neutralizing anti-
bodies (McLellan et al, 2011a; Correia et al, 2014; Luo et al, 2015).
The results obtained so far have had limited success, since the anti-
bodies induced in mice were not neutralizing despite being able to
bind hRSV F. Only in one case, in which site II was grafted onto an
immunoglobulin scaffold, did the resulting immunogen induce anti-
bodies in mice that neutralized hRSV in vitro, although with rela-
tively low efficiency (Luo et al, 2015). In another case, the site II
scaffold induced hRSV-neutralizing antibodies in macaques, but not
in mice, after repeated doses (Correia et al, 2014).
Because the recently solved structure of hMPV F in the postfu-
sion conformation revealed a high level of similarity with hRSV F,
particularly in antigenic site II, we hypothesized that exchanging
amino acids between the two proteins at that site should allow
proper folding and expression of chimeric molecules. Indeed,
proteins F-415 and F-416 displayed by EM the characteristic cone
shape of postfusion hMPV F, which was used as the backbone for
the chimeras (Fig EV1). In addition, by ELISA the chimeras showed
the antigenic characteristics of hRSV F site II (Fig 1C). In fact, F-416
showed an affinity for Mz similar to that of hRSV F although F-416
had a 10-fold reduced affinity for mAb 47F. Nevertheless, both F-
415 and F-416 were able to elicit in mice very significant antibody
responses against hRSV F (Fig 3). In addition, all mice immunized
with three doses of F-416 were fully protected against a hRSV chal-
lenge. Although only two mice inoculated with F-415 were protected
against hRSV, those mice were the ones with higher neutralizing
titers.
While the protection afforded by the chimeric proteins in the
experiment of Fig 4B cannot be ascribed exclusively to antibodies,
the relevance of antibodies in protection was substantiated by the
results of the adoptive transfer experiment of Fig EV3. Since other
studies have already demonstrated the capacity of postfusion hMPV
F to induce protective immune responses in cotton rats (Cseke et al,
2007), hamsters (Herfst et al, 2007), mice (Aerts et al, 2015), and
macaques (Herfst et al, 2008), the chimeric proteins could have the
advantage over the epitope scaffolding approach in that they would
confer protection simultaneously against more than one virus. This
possibility however needs to be tested directly in perhaps more
A B
Figure 6. Antibody responses of mice inoculated twice with either wild-type or chimeric proteins based on prefusion hRSV F.
Groups of BALB/c female mice (n = 5) were inoculated twice with 10 lg of the proteins indicated at the top of each panel, folded in either the prefusion conformation for hRSV
F, F-410, and F-411 or in the postfusion conformation for hMPV F. One week after the last dose, mice were sacrificed and their blood collected.
A Each mouse serum was tested in ELISA for antibody binding to the F proteins indicated at the bottom of each panel. *P = 0.00046 and **P = 0.02459.
B Mouse sera were also tested in microneutralization assays with hRSV and hMPV, indicated at the bottom. *P = 0.04138, **P = 0.04831 and ***P = 0.00339.
Data information: Each number represents an individual mouse. Short horizontal bars indicate mean values for each group. P-values were calculated as indicated under
“Statistical Analysis”. Only relevant P-values are shown. Differences were considered significant when P < 0.05. Long horizontal lines indicate detection limits.
EMBO Molecular Medicine Vol 10 | No 2 | 2018 ª 2017 The Authors
EMBO Molecular Medicine Chimeric Pneumoviridae fusion proteins Eduardo Olmedillas et al
182
permissive animal models such as cotton rats where protection in
the upper and lower respiratory tract against hRSV and hMPV could
be assessed. Additionally, non-human primates may be a more deci-
sive model to test an optimized chimeric F candidate.
While this work was being performed, Wen et al (2016) reported
a single chimeric hMPV F protein (RPM-1) that incorporated certain
site II amino acids from hRSV F. In contrast to the results reported
here, two high doses of RPM-1 failed to induce hRSV-neutralizing
antibodies in mice and only one out of five mice immunized with
RPM-1 elicited antibodies that bound faintly to hRSV F. Whether
differences in the amino acids substituted in the F proteins or
the different immunization protocols account for the discrepant
results reported by us and by Wen et al (2016) requires further
investigation.
Since the majority of neutralizing antibodies against hRSV in
humans recognize epitopes specific to prefusion F (Magro et al,
2012; Ngwuta et al, 2015; Gilman et al, 2016), it was important to
the test the feasibility of this conformation for grafting hMPV
antigenic sites. Indeed, F-410 and F-411 showed characteristics of
prefusion hRSV F by EM (Fig EV4) and by reactivity with conforma-
tion-specific mAbs (Fig EV5). At the same time, F-410 and F-411
gained reactivity, at least partially, with mAbs specific to hMPV site
IV. Both proteins elicited in mice polyclonal antibody responses that
bound hMPV F and neutralized this virus.
The chimeric protein approach described here undoubtedly
requires further optimization. Grafting of other antigenic sites, like
those specific to prefusion hRSV F, deserves being tested. The yield
of certain chimeric proteins, as shown in Fig EV1, turned out to be
extremely low. In that sense, it is worth noting that grafting of hRSV
site II yielded proteins that could be expressed and purified while
incorporation of hMPV F site II into either postfusion or prefusion
hRSV F ablated the expression of the matching chimeric proteins
(Fig EV1). Thus, fine tuning of changes introduced in chimeric
proteins may be critical for their expression and immunogenicity.
The use of other expression systems or incorporation of chimeric
proteins into viral vectors (Liang et al, 2017) or virus particles
(McGinnes et al, 2015) are alternatives to improve production and/
or immunogenicity of chimeric F proteins. Nonetheless, the results
presented here represent a proof of principle to design chimeric
proteins that may be used as single immunogens to induce cross-
neutralizing and cross-protecting immune responses against the
important Pneumoviridae members, hRSV and hMPV.
Materials and Methods
Cloning, expression, and purification of soluble forms of hRSV F
and hMPV F and chimeric derivatives
The following pRB21 (Blasco & Moss, 1995) plasmids encoding
soluble forms of either hRSV F or hMPV F proteins were used in this
study:
(i) pRB21/prefusion hRSV F (Pre-hRSV F): This plasmid encodes
the ectodomain of hRSV F (residues 1–524) from the Long
strain, stabilized in its prefusion conformation by incorporat-
ing the mutations described by McLellan et al (McLellan et al,
2013a) for the DS-Cav1 protein, which included addition of
both an intraprotomer disulfide bridge (S155C-S290C) and two
cavity-filling substitutions (S190F and V207L) (Palomo et al,
2016).
(ii) pRB21/postfusion hRSV F (Post-hRSV F): This plasmid encodes
residues 1–524 of the hRSV F ectodomain (Long strain) with a
deletion of the fusion peptide (residues 137–146) to avoid
aggregation (McLellan et al, 2011b; Palomo et al, 2016).
(iii) pRB21/postfusion hMPV F (Post-hMPV F). This plasmid
encodes residues 1–489 of the hMPV F ectodomain (NL/1/00)
in which the natural cleavage site was substituted by a polyba-
sic furin site and the first nine amino acids of the fusion
peptide (residues 103–111) were deleted (Mas et al, 2016).
Plasmids encoding the chimeras of Fig EV1 were obtained by
mutagenesis of the corresponding pRB21 plasmids using the
Phusion Site-Directed Mutagenesis kit (Thermo Fisher Scientific)
and designed primers, as recommended by the manufacturer.
Sequences of those primers can be obtained from the authors upon
request. In all cases, the foldon trimerization domain (Meier et al,
2004) was added at the C-terminus of the F protein ectodomain,
flanked upstream by a TEV protease site and downstream by a
Factor Xa protease site and 6xHis-tag.
The different plasmids were tested for transient expression of
the wild-type or chimeric proteins as follows: monolayers of CV-1
cells growing in DMEM supplemented with 10% fetal calf serum
(DMEM10) were infected with the furin-expressing vaccinia virus
VV:bfur (Vey et al, 1994) (m.o.i. 10 pfu/cell) followed by transfec-
tion with 5 lg/ml of each plasmid mixed with 15 lg/ml of Lipo-
fectamine 2000 (Invitrogen). Forty-eight hours later, the
supernatants were tested for the presence of wild-type or chimeric
proteins by ELISA, with the antibodies indicated in the figure
legends.
For large-scale production, vaccinia virus recombinants encoding
the chimeric proteins were obtained by the method of Blasco and
Moss (1995) based on recombination of vRB12 with pRB21 plas-
mids. The vaccinia strain vRB12 lacks most of the gene encoding
vp37 and hence is deficient in plaque formation under standard
conditions. pRB21-derived plasmids carry a complete copy of the
vp37 gene and thus, via homologous recombination with vRB12,
restore vp37 function.
Proteins were produced in CV-1 cells infected with the matching
vaccinia virus and purified from culture supernatants using Ni2+
columns followed by gel filtration on a HiLoad 16/600 Superdex
200 pg column, as described (Mas et al, 2016).
mAbs and Fab fragments
mAbs specific for either hRSV F or hMPV F are indicated and refer-
enced in the figure legends. Motavizumab [a more potent derivative
of palivizumab (Robbie et al, 2013)] was produced in HEK293 cells
transfected with plasmid DNA encoding the antibody heavy and
light chains and purified using Protein A-Sepharose. The Fab frag-
ment was generated by papain digestion (mass ratio 100:1) for 4 h
at 37°C, followed by passage over Protein A-Sepharose to remove
the Fc fragment. Antibody 47F (Garcia-Barreno et al, 1989) was
produced by growing the hybridoma cells in RPMI medium supple-
mented with 10% fetal calf serum. The antibody was purified from
culture supernatants as above and its Fab fragment produced as
described above.
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Surface plasmon resonance
All assays were run in a Biacore X100 instrument. An anti-6xHis mAb
was covalently coupled to both the sample and reference cells of a
CM5 chip at 10,000 response units (RU). Approximately 140 RU of
the proteins indicated in the figure legends were bound to the anti-
6xHis mAb, and then, the Fab fragments at 8–10 different protein
concentrations (0.5–500 nM) were injected. Binding data were fit to a
1:1 Langmuir binding model for calculation of the kinetic parameters.
Mouse immunization and virus challenge
Animal studies were performed under the regulations of the Spanish
and European legislation concerning vivisection and the use of geneti-
cally modified organisms. Protocols were approved by the “Comité
de Ética de la Investigación y del Bienestar Animal” of “Instituto de
Salud Carlos III” (CBA PA 19_2012). Specific pathogen-free 6- to 8-
week-old female BALB/c mice were obtained from ENVIGO (RMS,
Spain). Animals were group-housed in ventilated racks under a 12-h
light/12-h dark schedule at an ambient temperature of 21°C with food
and water available ad libitum. Group size was estimated using
previous published data (Mas et al, 2016), and no randomization
was used in grouping. No blinding procedure was used. In all experi-
ments, baseline antibodies (IgG) against both hRSV and hMPV post-
fusion were below the detection limit groups of 5–8 mice were
inoculated i.m. bilaterally in the quadriceps muscles (50 ll/site) with
the indicated amounts of proteins (see figure legends) in PBS mixed
with an equal volume of CpG (Magic Mouse adjuvant, Creative Diag-
nostics). The number of doses in 3–4 week intervals is indicated in
each figure legend. 1 or 2 weeks after the last dose, mice were bled
from the submandibular vein to obtain serum samples.
For challenge studies, mice were inoculated i.n. with 4 × 106 pfu
in 50 ll of PBS of the A2 strain of hRSV, which had been purified
from the supernatant of hRSV-infected cells by ultracentrifugation
(230,000 g/90 min) in a discontinuous sucrose gradient (30–45%
sucrose). Five days later, mice were euthanized, lungs removed and
extracts made in 5 ml of Dulbecco’s medium with 2.5% fetal calf
serum. hRSV titers in the lung extracts were determined by plaque
assay on HEp-2 cells (Gonzalez-Sanz et al, 2016).
Enzyme-linked immunosorbent assay (ELISA)
For testing mAb reactivity, 400 ng of purified mAbs in PBS was used
to coat 96-well microtiter plates. Non-specific binding was blocked
with 1% bovine serum albumin in PBS. Then, serial dilutions of the
different proteins were added to the wells for 1 h at room tempera-
ture, followed by an excess of an anti-His mAb (Bio-Rad, MCA
1396B), streptavidin–peroxidase, and substrate (OPD, GE Health-
care). Extensive washing with water was done after each step. Opti-
cal density was read at 492 nm.
For testing mouse serum reactivity, the microtiter plates were
coated with 80 ng/well of purified protein in 50 mM Na2HPO4, pH
8.0, 300 mM NaCl, and non-specific binding was blocked as above.
Then, serial dilutions of sera in blocking solution were added, and
bound antibodies were detected with peroxidase-labeled goat anti-
mouse Ig and OPD.
When sera were tested for binding to postfusion F proteins, the
foldon motif was removed from the ELISA antigen by pretreatment
with TEV protease and removal with Ni2+ columns to avoid binding
of anti-foldon antibodies present in the sera (Mas et al, 2016). In the
case of sera tested for binding to prefusion hRSV F, the anti-foldon
antibodies were first depleted by incubation with Ni2+ beads coated
with a MERS-CoV S1 protein containing a C-terminal foldon domain
and 8xHis-tag (Pallesen et al, 2017).
Microneutralization assay
GFP-expressing recombinant viruses derived from the A2 strain of hRSV
(a kind gift of Mark Peeples, Columbus, OH, USA) or the NL/1/00,
sublineage A1, of hMPV (a kind gift of Bernadette van den Hoogen
and Ron Fouchier, Rotterdam, the Netherlands) were mixed with
serial dilutions of mouse serum before being added to cultures of
Vero-118 cells growing in flat-bottom microtiter plates. Twenty-four
to forty-eight hours later, the medium was replaced by PBS and the
GFP fluorescence measured in a Tecan microplate reader M200.
Values were expressed as percent of a virus control without antibody.
Electron microscopy (EM)
Purified proteins were applied to glow-discharged carbon-coated
grids and negatively stained with 1% uranyl formate, as described
(Mas et al, 2016). Images were recorded on a Gatan ES1000W CCD
camera in a JEOL JEM-1011 microscope operated at 100 kV.
Statistical analysis
Animal sample sizes were chosen based on literature documenta-
tion and previous results obtained with similar experiments (Mas
The paper explained
Problem
hRSV and, to a lesser extent, hMPV are the main causes of severe ALRI
worldwide in very young children. Both viruses are members of the
same family (Pneumoviridae) that share many biological and clinical
characteristics, but they also have important differences. Although
much needed, no vaccine is available against either virus. The F glyco-
protein is the main target of neutralizing antibodies that correlate
with protection; however, no significant cross-neutralization between
hRSV and hMPV is observed in polyclonal responses raised against
their respective F antigens.
Results
Based on available structures of hRSV and hMPV F, a structure-based
approach was used to design chimeric F proteins in which particular
antigenic sites recognized by neutralizing antibodies were swapped
between the F glycoproteins of the two viruses. When inoculated into
mice, the chimeric proteins induced polyclonal antibody responses
that cross-neutralized both hRSV and hMPV and even protected
against challenge with the virus used for grafting of the heterologous
antigenic site.
Impact
These results demonstrate the feasibility of designing a single
immunogen capable of inducing polyclonal antibody responses that
neutralize both hRSV and hMPV, setting the stage for development of
cross-protective vaccines against human Pneumoviridae.
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et al, 2016). The number of animals used in each study is indi-
cated in the figure legends. No inclusion or exclusion criteria
were used, and studies were not blinded to investigators or
formally randomized. Results are expressed as individual values
and their mean. Statistical significance was calculated by one-way
ANOVA, followed by Tukey’s test using GraphPad Prism 6.
Expanded View for this article is available online.
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